WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, November 01, 2006

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT; PLUR=YES; OP=ADJ	
☐	L6	l4 and l5 and "[2,3-b]"	2
☐	L5	546/18	323
☐	L4	514/278	1388

END OF SEARCH HISTORY

=> d abs fbib hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB The title compds. (I) [Ar is selected from a 2-, or 3-linked thiophene, benzo[b]thiophene or benzo[c]thiophene substituted with 0, 1, 2 or 3 substituents independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n is 0, 1, or 2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.

AN 2003:837089 CAPLUS
DN 139:350723
TI Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003087103	A1	20031023	WO 2003-SE614	20030415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			SE 2002-1187	A 20020418
			SE 2002-3608	A 20021204
CA 2482312	AA	20031023	CA 2003-2482312	20030415
			SE 2002-1187	A 20020418
			SE 2002-3608	A 20021204
			WO 2003-SE614	W 20030415
AU 2003224545	A1	20031027	AU 2003-224545	20030415
			SE 2002-1187	A 20020418
			SE 2002-3608	A 20021204
			WO 2003-SE614	W 20030415
EP 1499615	A1	20050126	EP 2003-721208	20030415

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

			SE 2002-1187	A 20020418
			SE 2002-3608	A 20021204
			WO 2003-SE614	W 20030415
BR 2003009342	A	20050215	BR 2003-9342	20030415
			SE 2002-1187	A 20020418
			SE 2002-3608	A 20021204
			WO 2003-SE614	W 20030415
US 2005171106	A1	20050804	US 2003-511522	20030415
			SE 2002-1187	A 20020418
			SE 2002-3608	A 20021204
			WO 2003-SE614	W 20030415
JP 2005527588	T2	20050915	JP 2003-584059	20030415
			SE 2002-1187	A 20020418
			SE 2002-3608	A 20021204
			WO 2003-SE614	W 20030415
NO 2004004997	A	20050118	NO 2004-4997	20041117
			SE 2002-1187	A 20020418
			SE 2002-3608	A 20021204
			WO 2003-SE614	W 20030415

OS MARPAT 139:350723

IT 616875-54-8P 616875-55-9P 616875-56-0P
616875-57-1P 616875-58-2P 616875-59-3P
616875-60-6P 616875-61-7P 616875-62-8P
616875-63-9P 616875-64-0P 616875-65-1P
616875-66-2P 616875-67-3P 616875-68-4P
616875-69-5P 616875-70-8P 616875-71-9P
616875-72-0P 616875-73-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienylspiro[1-azabicyclo[2.2.2]octane-furo[2,3-b]pyridine] derivs. as agonists of α7 nicotinic receptor for treatment or prophylaxis of psychotic disorders or intellectual impairment disorders)

RN 616875-54-8 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-thienyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-55-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-thienyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-56-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-benzo[b]thien-2-yl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-57-1 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-benzo[b]thien-3-yl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-58-2 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-methyl-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-59-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(4-methyl-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-60-6 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-2-thienyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-61-7 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-3-thienyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-62-8 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-63-9 CAPLUS
CN 2-Thiophenecarbonitrile, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 616875-64-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-methyl-3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-65-1 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-66-2 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-67-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-68-4 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-69-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-fluoro-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-70-8 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-bromo-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-71-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-fluoro-3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-72-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-bromo-3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-73-1 CAPLUS
CN 2-Thiophenecarbonitrile, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
GI



II

AB RNR1R2 [R = spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine]-5- or -6-yl][I; R1 = (hetero)aryl(alkyl), CH2CH:CHR3, CH2C.tplbond.CR3; R2 = H, alkyl, CHO, alkanoyl, alkoxycarbonyl, etc.; R3 = (hetero)aryl(alkyl)] were prepared Thus, quinuclidin-3-one underwent methylene insertion with Me3S(O)I and the N-BH3-complexed epoxide condensed with 2-chloropyridine to give, in 3 addnl. steps, (S)- and (R)-RH the latter of which was converted in 3 addnl. steps to title compound (R)-II. Data for biol. activity of I were given.

AN 2000:493546 CAPLUS
DN 133:120318
TI Preparation of furopyridineamines as nicotinic receptor agonists
IN Loch, James, III; Mullen, George; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042044	A1	20000720	WO 1999-SE2478	19991223
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				SE 1999-100	A 19990115
	CA 2359990	AA	20000720	CA 1999-2359990	19991223
				SE 1999-100	A 19990115
				WO 1999-SE2478	W 19991223
	EP 1147114	A1	20011024	EP 1999-967044	19991223
	EP 1147114	B1	20030521		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				SE 1999-100	A 19990115
				WO 1999-SE2478	W 19991223
	BR 9916906	A	20011030	BR 1999-16906	19991223
				SE 1999-100	A 19990115
				WO 1999-SE2478	W 19991223
	TR 200102042	T2	20020521	TR 2001-200102042	19991223

			SE 1999-100	A	19990115
EE 200100370	A	20021015	EE 2001-370		19991223
EE 4528	B1	20050815			
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
JP 2002534525	T2	20021015	JP 2000-593611		19991223
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
AT 240960	E	20030615	AT 1999-967044		19991223
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
NZ 512733	A	20030829	NZ 1999-512733		19991223
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
PT 1147114	T	20031031	PT 1999-967044		19991223
			SE 1999-100	A	19990115
CN 1132837	B	20031231	CN 1999-816422		19991223
			SE 1999-100	A	19990115
ES 2200590	T3	20040301	ES 1999-967044		19991223
			SE 1999-100	A	19990115
RU 2233282	C2	20040727	RU 2001-122812		19991223
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
AU 775433	B2	20040729	AU 2000-23343		19991223
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
TW 227237	B1	20050201	TW 2000-89100989		20000121
			SE 1999-100	A	19990115
US 2003149065	A1	20030807	US 2000-529654		20000418
US 6995167	B2	20060207			
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
ZA 2001005527	A	20021004	ZA 2001-5527		20010704
			SE 1999-100	A	19990115
NO 2001003478	A	20010914	NO 2001-3478		20010713
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
HK 1040517	A1	20030905	HK 2002-102161		20020321
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
US 2005250802	A1	20051110	US 2005-181098		20050714
			SE 1999-100	A	19990115
			WO 1999-SE2478	W	19991223
			US 2000-529654	A3	20000418

OS MARPAT 133:120318

IT 284486-13-1P 284486-23-3P 284486-39-1P
284486-42-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furopyridineamines as nicotinic receptor agonists)

RN 284486-13-1 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-amine, N-(2-thienylmethyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 284486-23-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-amine, N-(3-thienylmethyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 284486-39-1 CAPLUS
CN Acetamide, N-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 284486-42-6 CAPLUS
CN Ethanol, 2-[(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl(3-thienylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
Uploading C:\Program Files\Stnexp\Queries\10511522.str





ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 8-15 8-16 10-11 10-14 11-12
12-13 13-14 15-19 15-21 16-17 17-18 17-20 18-19 20-21
exact/norm bonds :
2-7 3-9 7-8 8-9 8-15 8-16 10-11 10-14 11-12 12-13 13-14 15-19 15-21
16-17 17-18 17-20 18-19 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l5
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 10:58:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 1 TO 80

L6 1 SEA SSS SAM L5

L7 1 L6

=> d abs bib hitstr

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB The title compds. (I) [Ar is selected from a 2-, or 3-linked thiophene, benzo[b]thiophene or benzo[c]thiophene substituted with 0, 1, 2 or 3 substituents independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n is 0, 1, or 2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.

AN 2003:837089 CAPLUS

DN 139:350723

TI Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor

IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087103	A1	20031023	WO 2003-SE614	20030415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482312	AA	20031023	CA 2003-2482312	20030415

	AU 2003224545	A1	20031027	AU 2003-224545	20030415
	EP 1499615	A1	20050126	EP 2003-721208	20030415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009342	A	20050215	BR 2003-9342	20030415
	US 2005171106	A1	20050804	US 2003-511522	20030415
	JP 2005527588	T2	20050915	JP 2003-584059	20030415
	NO 2004004997	A	20050118	NO 2004-4997	20041117
PRAI	SE 2002-1187	A	20020418		
	SE 2002-3608	A	20021204		
	WO 2003-SE614	W	20030415		

OS MARPAT 139:350723

IT 616875-73-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienylspiro[1-azabicyclo[2.2.2]octane-furo[2,3-b]pyridine] derivs. as agonists of α7 nicotinic receptor for treatment or prophylaxis of psychotic disorders or intellectual impairment disorders)

RN 616875-73-1 CAPLUS

CN 2-Thiophenecarbonitrile, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.03	188.44
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-2.25

FILE 'REGISTRY' ENTERED AT 10:59:47 ON 03 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9
DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s l5 ful
FULL SEARCH INITIATED 10:59:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      326 TO ITERATE

100.0% PROCESSED      326 ITERATIONS                          24 ANSWERS
SEARCH TIME: 00.00.03

L8            24 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             166.94     355.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -2.25

FILE 'CAPLUS' ENTERED AT 10:59:58 ON 03 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 3 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 2 Mar 2006 (20060302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l8
L9 2 L8

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	355.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.25

STN INTERNATIONAL LOGOFF AT 11:00:33 ON 03 MAR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA

```
 NEWS 15   FEB 21  STN AnaVist, Version 1.1, lets you share your STN AnaVist
                   visualization results
 NEWS 16   FEB 22  Status of current WO (PCT) information on STN
 NEWS 17   FEB 22  The IPC thesaurus added to additional patent databases on STN
 NEWS 18   FEB 22  Updates in EPFULL; IPC 8 enhancements added
 NEWS 19   FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS 20   FEB 28  MEDLINE/LMEDLINE reload improves functionality
 NEWS 21   FEB 28  TOXCENTER reloaded with enhancements
 NEWS 22   FEB 28  REGISTRY/ZREGISTRY enhanced with more experimental spectral
                   property data
 NEWS 23   MAR 01  INSPEC reloaded and enhanced

 NEWS EXPRESS  FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:22:51 ON 03 MAR 2006

=> file caplus
```

```
=> s pain and ( alpha 7 nicotinic receptor)
         42531 PAIN
           990 PAINS
         43214 PAIN
                 (PAIN OR PAINS)
       1594023 ALPHA
          2475 ALPHAS
       1594124 ALPHA
                 (ALPHA OR ALPHAS)
       2627269 7
         35914 NICOTINIC
             1 NICOTINICS
         35915 NICOTINIC
                 (NICOTINIC OR NICOTINICS)
        639778 RECEPTOR
        586825 RECEPTORS
        761496 RECEPTOR
                 (RECEPTOR OR RECEPTORS)
           305 ALPHA 7 NICOTINIC RECEPTOR
                 (ALPHA(W)7(W)NICOTINIC(W)RECEPTOR)
L1          21 PAIN AND ( ALPHA 7 NICOTINIC RECEPTOR)

=> d abs bib hitstr 1-10

L1   ANSWER 1 OF 21  CAPLUS  COPYRIGHT 2006 ACS on STN
AB   Background: A recent model of acute incisional pain has been
     characterized that strongly parallels the postoperative period in patients
     experiencing evoked pain.  In that setting, abundant literature
     has revealed antihypersensitive effects produced by intrathecally
     administered α2-adrenergic receptor agonists, such as clonidine, in
     both animals and humans.  Recent reports have suggested an obligatory role
     of spinal acetylcholine receptors in the analgesic action of intrathecal
     clonidine.  The authors sought to determine the involvement of spinal
     muscarinic and nicotinic receptor subpopulations in the
     antihypersensitivity effect of intrathecal clonidine in a rodent model for
     human postoperative pain.  Methods: After intrathecal
     catheterization, rats underwent superficial plantar incision.  Clonidine
     or a combination of clonidine and muscarinic receptor subtype antagonists
     (M1, M2, M3, and M4) or nicotinic receptor subtype antagonists
     (α4β2 and α7) were intrathecally administered, and
     withdrawal thresholds to mech. stimuli were examined  Results: Spinal
     clonidine maximally reduced hypersensitivity adjacent to the wound 30 min
     after its injection.  When animals were intrathecally pretreated with the
     M1 muscarinic antagonist toxin MT-7, the M3 muscarinic antagonist
     4-diphenylacetoxy-N-methylpiperidine, and the M4 muscarinic antagonist
     toxin MT-3, clonidine lost its antihypersensitive action.  When animals
     were intrathecally pretreated with the α4β2 nicotinic receptor
     antagonist dihydro-β-erythroidine, but not with the  α
     7 nicotinic receptor antagonist
     methyllycaconitine, the antihypersensitivity action of clonidine was
     abolished.  Conclusions: These data indicate for the first time that the
     clonidine-induced increase in punctuate mech. threshold is mediated via
     the activation of all but M2 muscarinic receptor subtypes, and via the
     activation of α4β2 but not  .alpha.7
     nicotinic receptor subtypes in a rodent model for human
     postoperative pain.
AN   2005:1241528  CAPLUS
TI   Spinal Muscarinic and Nicotinic Subtypes Activated by Clonidine in
```

Postincisional Pain

AU Duflo, Frederic; Boselli, Emmanuel; Ryvlin, Philippe; Chassard, Dominique
CS Department of Anesthesiology and Intensive Care, Hopital de l'Hotel-Dieu, Lyon, Fr.

SO Anesthesiology (2005), 103(6), 1253-1258
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I



II



III



IV



V

AB The invention relates to heteroaryl-substituted azabicyclic compds., e.g., I or II, which are ligands for nicotinic acetylcholine receptors (nAChR) and can be used for the activation of nAChRs and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. In compds. I and II, B is CH2, C=O, or C=S; m is 1 or 2; Y is O or S; X1 to X4 are independently selected from N and (un)substituted C, wherein at most one of X1 to X4 is N; X5 and X6 are independently selected from CH, fluoro-substituted C1-6 alkoxy-C, and heterocyclyl-C, wherein no more than one of X5 and X6 is CH; X7 is CH or N; and R is H, (halo)-C1-4 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, and C1-6 alkyl-C6-10 aryl. The invention also relates to

the preparation of the heteroaryl-substituted diazabicyclic compds., pharmaceutical compns. comprising those compds. and a pharmaceutically acceptable carrier, as well as to the use of the compns. as agonists for the α7 nAChR subtype. Acylation of 3-methoxythiophenol with oxalyl chloride followed by cyclization gave benzothiophenedione III, which underwent oxidative cleavage resulting in the formation of benzoisothiazolecarboxamide IV. Alkaline hydrolysis of IV to the carboxylic acid was followed by coupling with 1,4-diazabicyclo[3.2.2]nonane to give compound V. The preferred compds. of the invention express binding affinities of 5 nM to 2.5 μM (no data).

AN 2005:1241229 CAPLUS
DN 144:6818
TI Indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones as .alpha.7 nicotinic receptor agonists, their preparation, pharmaceutical compositions, and use in therapy
IN Xie, Wenge; Herbert, Brian; Schumacher, Richard A.; Ma, Jianguo; Nguyen, Truc Minh; Gauss, Carla Maria; Tehim, Ashok
PA Memory Pharmaceuticals Corporation, USA
SO PCT Int. Appl., 143 pp., which which
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005111038	A2	20051124	WO 2005-US15937	20050506
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005272735	A1	20051208	US 2005-123219	20050506
PRAI	US 2004-568696P	P	20040507		
	US 2004-574712P	P	20040527		
	US 2004-626469P	P	20041110		
	US 2004-629469P	P	20041119		

OS MARPAT 144:6818

L1 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB The title compds. I [A and B = H, halo, alkoxy, amino, etc.; X1, X2 = C, CH, N; provided that when one of X1 and X2 = N, thee other + C or CH; Y1 = C(O), CH2, CH(OH), C(S), etc.; Y2 is a bond or Y2 = O, S, and N(R12); R12 = H, alkyl; Rx = H, halo, alkoxy, amino, alkylamino, dialkylamino, acylamino, dialkylaminoalkyl, and cyano; a = 0-1; b = 0-1; provided that when one of a and b = 0, the other = 1] and compns. containing I are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands that encompass compds. I and other tricyclic derivs. Compds. I had Ki values of from .apprx.1 nM to .apprx.10 μM when tested by the [3H]-methyllycaconitine binding assay, many having a Ki of <1 μM. (3H)-Cytisine binding values of I ranged from .apprx.50 nM to at least 100 μM. Preferred compds. typically exhibited greater potency at α7 receptors compared to α4β2 receptors. Although the methods of preparation are not claimed, 67 example prepns. are included. For example, 2,7-bis[((2R)-1-methylpyrrolidin-2-yl)methoxy]fluoren-9-one di-p-toluenesulfonate was prepared in 4 steps (54, 89, 26 and 74 % yields) starting from 2,7-dihydroxyfluoren-9-one, (2R)-(+)-1-Boc-2-pyrrolidinemethanol and involving intermediates 2,7-bis[((2R)-1-Boc-pyrrolidin-2-yl)methoxy]fluoren-9-one, 2,7-bis[((2R)-pyrrolidin-2-yl)methoxy]fluoren-9-one, and 2,7-bis[((2R)-1-methylpyrrolidin-2-yl)methoxy]fluoren-9-one.

AN 2005:1132908 CAPLUS

DN 143:405799

TI Preparation of amino-substituted tricyclic derivatives as modulators of .alpha.7 nicotinic receptors and methods of use

IN Schrimpf, Michael R.; Sippy, Kevin B.; Ji, Jianguo; Li, Tao; Frost, Jennifer M.; Briggs, Clark A.; Bunnelle, William H.

PA USA

SO U.S. Pat. Appl. Publ., 90 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005234031	A1	20051020	US 2005-51437	20050204
PRAI	US 2004-541651P	P	20040204		

L1 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

GI



I

AB Amino-substituted tricyclic derivs. (shown as I; variables defined below; e.g. 2,7-Bis[((2R)-1-methylpyrrolidin-2-yl)methoxy]fluoren-9-one di-p-toluenesulfonate (II)) and compns. containing I are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands that encompass compds. I and other tricyclic derivs. Compds. I had Ki values of from .apprx.1 nM to

.apprx.10 μM when tested by the [3H]-methyllycaconitine binding assay, many having a Ki of <1 μM. (3H)-Cytisine binding values of I ranged from .apprx.50 nM to at least 100 μM. Preferred compds. typically exhibited greater potency at α7 receptors compared to α4β2 receptors. For I: A and B = H, halogen, alkoxy, amino, alkylamino, acylamino, dialkylamino, cyano, nitro, and -SO3H, -C.tplbond.CCH2NR7R8 and -O-[C(R20)2-3N(R21)(R22)], et al.; Y1 = -C(O)-, -CH2-, -CH(OH)-, -C(S)-, -N(R11)-, -O-, -S-, -S(O)-, -S(O)2-, -C(O)NH-, and -S(O)2NH-; Y2 is a bond or Y2 = -O-, -S-, and -N(R12)-; Rx = H, halogen, alkoxy, amino, alkylamino, dialkylamino, acylamino, dialkylaminoalkyl, and cyano; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, 22 example prepns. are included. For example, II was prepared in 4 steps (54, 89, 26 and 74 % yields) starting from 2,7-dihydroxyfluoren-9-one, (2R)-(+)-1-Boc-2-pyrrolidinemethanol and involving intermediates 2,7-bis[((2R)-1-Boc-pyrrolidin-2-yl)methoxy]fluoren-9-one, 2,7-bis[((2R)-pyrrolidin-2-yl)methoxy]fluoren-9-one, and 2,7-bis[((2R)-1-methylpyrrolidin-2-yl)methoxy]fluoren-9-one.

AN 2005:698355 CAPLUS
DN 143:172757
TI Preparation of amino-substituted tricyclic derivatives as modulators of .alpha.7 nicotinic receptors and methods of use
IN Schrimpf, Michael R.; Sippy, Kevin B.; Ji, Jianguo; Li, Tao; Pace, Jennifer M.; Briggs, Clark A.
PA USA
SO U.S. Pat. Appl. Publ., 67 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005171079	A1	20050804	US 2004-772192	20040204
WO 2005077899	A2	20050825	WO 2005-US3578	20050204
WO 2005077899	A3	20051201		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-772192 A 20040204
OS MARPAT 143:172757

L1 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AB The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compds. for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compds., compns. containing such compds., and methods of use thereof.

AN 2005:612302 CAPLUS
DN 143:133366
TI Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
IN Xie, Wenge; Herbert, Brian; Ma, Jianguo; Nguyen, Truc Minh; Schumacher, Richard A.; Gauss, Carla-Maria; Tehim, Ashok
PA Memory Pharmaceuticals Corporation, USA
SO PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063767	A2	20050714	WO 2004-US42852	20041222
	WO 2005063767	A3	20050825		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005176754	A1	20050811	US 2004-18429	20041222
PRAI	US 2003-530891P	P	20031222		
	US 2004-606897P	P	20040903		

OS MARPAT 143:133366

L1 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB Nicotine derivs. I [D = O, S; E = single bond, O, S, NR1; Ar1, Ar2 = (hetero)aryl; R1 = undefined] were prepared for treating conditions affected by the activation of .alpha.7 nicotinic receptors. These conditions include psychotic, neurol.., and intellectual impairment disorders.
AN 2005:588959 CAPLUS
DN 143:97559
TI Preparation and use of nicotinic acetylcholine receptor ligands for treating neurological, psychotic and intellectual impairment disorders
IN Ernst, Glen; Jacobs, Robert; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005061495	A1	20050707	WO 2004-SE1943	20041220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-531648P P 20031222
OS MARPAT 143:97559
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I



II

AB Nicotine derivs. I [D = O, S; E = single bond, O, S, NR1; Ar1, Ar2 = (hetero)aryl; R1 = undefined] were prepared for treating conditions affected by the activation of .alpha.7 nicotinic receptors. These conditions include psychotic, neurol., and intellectual impairment disorders. As an example of the synthesis, 4-fluorobiphenyl-3-carboxylic acid reacted with (R)-(+)-3-aminoquinuclidine dihydrochloride to give the desired product II.
AN 2005:588957 CAPLUS
DN 143:97558
TI Preparation and use of nicotinic acetylcholine receptor ligands for treating neurological, psychotic and intellectual impairment disorders
IN Ernst, Glen; Jacobs, Robert; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005061494	A1	20050707	WO 2004-SE1940	20041220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG
PRAI US 2003-531712P P 20031222
OS MARPAT 143:97558
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AB Although chronic nicotine produces dependence in mice, the role of specific nicotinic receptors has not been examined in knockout animals. The present study utilized .alpha.7 nicotinic receptor knockout mice to explore the role of this receptor subunit in nicotine dependence. Mice were chronically exposed to nicotine (0 or 200 μg/mL) in their drinking water and assayed for somatic withdrawal signs, hyperalgesia (tail-flick and hot-plate) and spontaneous activity following nicotine cessation. Nicotine withdrawal produced increased somatic signs in both strains and hyperalgesia in wild-type, but not in knockout animals. These results indicate that the .alpha .7 nicotinic receptor subunit may mediate some aspects of nicotine dependence.
AN 2005:465257 CAPLUS
DN 143:54880
TI Nicotine physical dependence in the mouse: Involvement of the . alpha.7 nicotinic receptor subtype
AU Grabus, Sheri D.; Martin, Billy R.; Imad Damaj, M.
CS Department of Pharmacology & Toxicology, Virginia Commonwealth University Medical Campus, Richmond, VA, 23298-0613, USA
SO European Journal of Pharmacology (2005), 515(1-3), 90-93
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AB We used the hot plate test and the formalin test to evaluate the antinociception of choline after i.c.v. or i.v. administration. The analgesic mechanism of choline was also studied. The response latency of mice was significantly prolonged in the hot plate test after choline (90-120 μg/animals) i.c.v. administration in a dose-dependent manner. Pretreatment with methyllycaconitine citrate (MLA), α-bungarotoxin, or atropine blocked the antinociception of choline in the hot plate test. In contrast, mecamylamine and naloxone had no effect. No antinociceptive action of choline was found in the hot plate test, but it did have an effect in the late phase of the formalin test after i.v. administration. The effect of choline on anti-inflammatory pain was blocked by MLA, but not by mecamylamine, naloxone and atropine, which is indicative of the involvement of α7 receptors in peripheral sites. When choline (2 mg/kg) was coadministered with aspirin (9.4 mg/kg), the licking/biting times in the late phase significantly decreased, although no effects were shown when these doses of drugs were used alone. Similarly, coadministration of choline (2 mg/kg) with morphine (0.165

mg/kg) significantly increased the antinociception of morphine in the late phase, but had no effect in the early phase. These results demonstrate that activation of .alpha.7 nicotinic receptors by choline elicits antinociceptive effects both in an acute thermal pain model and in an inflammatory pain model. Choline holds promise for development as a non-addictive analgesic drug and in reducing the regular dose of aspirin or morphine in inflammatory pain.

AN 2005:244433 CAPLUS
DN 142:329694
TI Antinociceptive effects of choline against acute and inflammatory pain
AU Wang, Y.; Su, D.-M.; Wang, R.-H.; Liu, Y.; Wang, H.
CS Thadweik Academy of Medicine, Beijing, 100850, Peop. Rep. China
SO Neuroscience (Oxford, United Kingdom) (2005), 132(1), 49-56
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier Ltd.
DT Journal
LA English
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB The invention discloses preparation of quinuclidine-substituted benzodioxine carboxamide derivs., such as I.X [X = malate salt, including D- or L-(II)], or pharmaceutical composition, racemic mixture, or pure enantiomer thereof, to treat diseases or conditions in which α 7 nicotinic receptor is known to be involved. Thus, reaction between 1,4-benzodioxane-6-carboxylic acid and 3(R)-aminoquinuclidine dihydrochloride yielded I, which on treatment with L-malic acid, afforded I.L-malate (III). The prepared benzodioxine carboxamide derivs. II are useful for the treatment of neurodegenerative diseases.

AN 2004:996175 CAPLUS
DN 141:411133
TI Preparation of quinuclidine substituted benzodioxine carboxamides for the treatment of neurodegenerative diseases
IN Selbo, John Gordon; Hawley, Michael; Jin, Qingwu; Walker, Daniel Patrick
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2004099202	A1	20041118	WO 2004-IB1421	20040422
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005059698	A1	20050317	US 2004-838596	20040504
PRAI	US 2003-467898P	P	20030505		
RE.CNT	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

Uploading C:\Program Files\Stnexp\Queries\19511522.str





chain nodes :
17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
8-17
ring bonds :
1-2 1-5 1-9 2-3 3-4 3-10 3-11 4-5 5-6 6-7 7-8 8-9 10-13 10-15 11-12 12-14 12-16 13-14 15-16
exact/norm bonds :
1-2 2-3 3-4 3-10 3-11 4-5 8-17 10-13 10-15 11-12 12-14 12-16 13-14 15-16

normalized bonds :
1-5 1-9 5-6 6-7 7-8 8-9

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
Element Count :
Node 17: Limited
S,S1

L20 STRUCTURE UPLOADED

=> s l20
SAMPLE SEARCH INITIATED 17:22:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6 TO 266
PROJECTED ANSWERS: 1 TO 80

L21 1 SEA SSS SAM L20

```
=> s l20 ful
FULL SEARCH INITIATED 17:22:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      214 TO ITERATE

100.0% PROCESSED      214 ITERATIONS                          31 ANSWERS
SEARCH TIME: 00.00.01

L22          31 SEA SSS FUL L20

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                              166.94    1048.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -9.00

FILE 'CAPLUS' ENTERED AT 17:23:02 ON 11 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 11 Aug 2006  VOL 145 ISS 8
FILE LAST UPDATED: 10 Aug 2006  (20060810/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l22
L23          2 L22

=> d abs bib hitstr 1-2

L23  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
GI
```



I

AB The title compds. (I) [Ar is either a monocyclic 5-membered ring heterocycle or a bicyclic benzo-fused 5-membered ring heterocycle connected via the 5-membered ring, having, as part of the five membered ring, one ring nitrogen atom and either one ring oxygen atom or one ring sulfur atom, said monocyclic or fused bicyclic ring heterocycle being substituted with 0, 1, or 2 substituents selected from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n = 0-2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.

AN 2003:837090 CAPLUS <<LOGINID::20060811>>

DN 139:350726

TI Preparation of (2'R)-5'-heterocyclylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor

IN Chang, Hui-Fang; Phillips, Eifion

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087104	A1	20031023	WO 2003-SE615	20030415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482313	AA	20031023	CA 2003-2482313	20030415
	AU 2003224546	A1	20031027	AU 2003-224546	20030415
	EP 1499616	A1	20050126	EP 2003-721209	20030415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009345	A	20050215	BR 2003-9345	20030415

	US 2005131003	A1	20050616	US 2003-511525	20030415
	CN 1662542	A	20050831	CN 2003-813901	20030415
	JP 2005534624	T2	20051117	JP 2003-584060	20030415
	ZA 2004008338	A	20051102	ZA 2004-8338	20041014
	NO 2004004995	A	20050118	NO 2004-4995	20041117
PRAI	SE 2002-1185	A	20020418		
	SE 2002-3606	A	20021204		
	WO 2003-SE615	W	20030415		

OS MARPAT 139:350726

IT 616876-21-2P 616876-22-3P 616876-23-4P
616876-24-5P 616876-25-6P 616876-29-0P
616876-30-3P 616876-31-4P 616876-35-8P
616876-36-9P 616876-42-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylspiro[1-azabicyclo[2.2.2]octane-furo[2,3-b]pyridine] derivs. as agonists of α7 nicotinic receptor for treatment or prophylaxis of psychotic disorders or intellectual impairment disorders)

RN 616876-21-2 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-thiazolyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616876-22-3 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(4-thiazolyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616876-23-4 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-thiazolyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616876-24-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-methyl-5-thiazolyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616876-25-6 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-benzothiazolyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616876-29-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-thiazolyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616876-30-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(4-thiazolyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616876-31-4 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-thiazolyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616876-35-8 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-[2-(trifluoromethyl)-4-thiazolyl]-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616876-36-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-[2-(trifluoromethyl)-5-thiazolyl]-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616876-42-7 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-methyl-4-thiazolyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB The title compds. (I) [Ar is selected from a 2-, or 3-linked thiophene, benzo[b]thiophene or benzo[c]thiophene substituted with 0, 1, 2 or 3 substituents independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n is 0, 1, or 2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or

prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.

AN 2003:837089 CAPLUS <<LOGINID::20060811>>

DN 139:350723

TI Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor

IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087103	A1	20031023	WO 2003-SE614	20030415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482312	AA	20031023	CA 2003-2482312	20030415
	AU 2003224545	A1	20031027	AU 2003-224545	20030415
	EP 1499615	A1	20050126	EP 2003-721208	20030415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009342	A	20050215	BR 2003-9342	20030415
	US 2005171106	A1	20050804	US 2003-511522	20030415
	CN 1659170	A	20050824	CN 2003-813782	20030415
	JP 2005527588	T2	20050915	JP 2003-584059	20030415
	ZA 2004008339	A	20051103	ZA 2004-8339	20041014
	NO 2004004997	A	20050118	NO 2004-4997	20041117
PRAI	SE 2002-1187	A	20020418		
	SE 2002-3608	A	20021204		
	WO 2003-SE614	W	20030415		

OS MARPAT 139:350723

IT 616875-54-8P 616875-55-9P 616875-56-0P
616875-57-1P 616875-58-2P 616875-59-3P
616875-60-6P 616875-61-7P 616875-62-8P
616875-63-9P 616875-64-0P 616875-65-1P
616875-66-2P 616875-67-3P 616875-68-4P
616875-69-5P 616875-70-8P 616875-71-9P

616875-72-0P 616875-73-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienylspiro[1-azabicyclo[2.2.2]octane-furo[2,3-b]pyridine] derivs. as agonists of α7 nicotinic receptor for treatment or prophylaxis of psychotic disorders or intellectual impairment disorders)

RN 616875-54-8 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-thienyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-55-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-thienyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-56-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-benzo[b]thien-2-yl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-57-1 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-benzo[b]thien-3-yl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-58-2 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-methyl-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-59-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(4-methyl-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-60-6 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-2-thienyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-61-7 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-3-thienyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-62-8 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-63-9 CAPLUS
CN 2-Thiophenecarbonitrile, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-

furo[2,3-b]pyridin]-5'-yl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616875-64-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-methyl-3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-65-1 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-66-2 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-67-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-68-4 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-69-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-fluoro-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-70-8 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-bromo-2-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-71-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-fluoro-3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-72-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-bromo-3-thienyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616875-73-1 CAPLUS
CN 2-Thiophenecarbonitrile, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


S
NC
N
R
O
N